Peloton Therapeutics raises USD 150 Million for treating Advance Kidney Cancer
Peloton Therapeutics has been in the process of developing small molecule drugs to treat Cancer, has raised USD 150 million. Peloton’s lead therapeutic candidate, PT2977, focuses on targeting hypoxia-inducible factor-2a, or HIF-2a, in Renal cell carcinoma. The drug has probable chances for treatment of Von Hippel-Lindau disease, a genetic cancer syndrome which at present has no approved drugs.
BiomX raises USD 32 Million to eliminate bacteria
BiomX has netted USD 32 million to eliminate the existence of bacteria causing...
